No Data
No Data
Artiva Biotherapeutics to Reveal Longer-term Phase 1/2 Data For AlloNK in Combination With Rituximab In Patients With B-cell-Non-Hodgkin Lymphoma At the ASGCT 28th Annual Meeting
Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK in Combination With Rituximab in Patients With B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting
Needham Maintains Artiva Biotherapeutics(ARTV.US) With Buy Rating, Maintains Target Price $23
Press Release: Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer
Artiva Biotherapeutics Price Target Maintained With a $23.00/Share by Needham
Promising Outlook for Artiva Biotherapeutics Amid Strategic Manufacturing and Regulatory Support